【摘要】  目的   探讨ɑ糖苷酶抑制剂与DPP-4抑制剂联合应用治疗T2DM患者的有效性及安全性。  方法   将120例T2DM患者随机分为观察组和对照组，各60例。观察组采用ɑ糖苷酶抑制剂与DPP4抑制剂联合治疗，对照组单独应用DPP-4抑制剂治疗，随访16周，测定治疗前后血糖、生化相关指标，观察不良反应发生情况及治疗对C-P的影响。  结果   治疗后，观察组FPG[（7.14±1.41） vs （9.02±1.11） mmol/L]、2 hPG[（9.85±1.59） vs （15.28±1.08） mmol/L]及HbA1c[（6.68±1.24）% vs （8.24±1.92）%]水平下降；C-RP[（5.14±1.21） vs （8.82±1.71） mg/L]水平降低；观察组HbA1c的达标率高于对照组[76.67%（46/60） vs 63.33%（38/60）]（P＜0.05）。两组血糖指标和C-P水平治疗前后差值（Δ值）比较，差异有统计学意义（P＜0.05）。  结论   ɑ糖苷酶抑制剂与DPP4抑制剂联合应用与单独应用DPP-4抑制剂相比，治疗T2DM效果更好，且降低血清C-P效果更佳。
    【关键词】  ɑ糖苷酶抑制剂；DPP-4抑制剂；糖尿病，2型

  Efficacy of ɑ-glucosidase inhibitor in combination with DPP-4 inhibitor on type 2 diabetic mellitus 
    【Abstract】  Objective   To investigate the efficacy and safety of ɑ-glucosidase inhibitor in combination with DPP-4 inhibitor on type 2 diabetes mellitus.  Methods   A total of 120 patients with T2DM were randomly divided into two groups: observation group using ɑ-glucosidase inhibitor in combination with DPP-4 inhibitor (n=60) and control group treated with DPP-4 inhibitor monotherapy (n=60). All patients were followed up for 16 weeks. Blood glucose and biochemical indices were measured at baseline and after treatment. Adverse events and effect of treatment on C-P were observed.  Results   After treatment, FPG[（7.14±1.41）vs（9.02±1.11）mmol/L], 2 hPG[（9.85±1.59）vs（15.28±1.08）mmol/L], HbA1c[（6.68±1.24）% vs（8.24±1.92）%] and C-RP level[（5.14±1.21）vs（8.82±1.71） mg/L] were lower in observation group than in control group. Proportion of patients with targeted HbA1c was higher in observation group than in control group [76.67% (46/60) vs 63.33%(38/60)] (P＜0.05). The differences (Δ value) of blood glucose indicators and C-P level between baseline and after-treatment in both groups were statistically significant (P＜0.05).  Conclusion   ɑ-glucosidase inhibitor in combination with DPP-4 inhibitor has a better effect on T2DM treatment and C-P level than DPP-4 inhibitor monotherapy.
    【Key words】  ɑ-glucosidase inhibitor; DPP-4 inhibitor; Diabetes mellitus, type 2